reports
Gilead Sciences Inc: 2 directors
Two Directors at Gilead Sciences Inc sold/sold after exercising options 50,603 shares at between 83.782USD and 84.500USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all...
- Dave Nicoski
- Ross LaDuke
ILMN ILLUMINA INC.
KMX CARMAX INC.
TFX TELEFLEX INCORPORATED
OMCL OMNICELL INC.
MDT MEDTRONIC PLC
MD MEDNAX INC.
LAD LITHIA MOTORS INC. CLASS A
JNJ JOHNSON & JOHNSON
GILD GILEAD SCIENCES INC.
EXPE EXPEDIA GROUP INC.
CNMD CONMED CORPORATION
CHTR CHARTER COMMUNICATIONS INC. CLASS A
BXP BOSTON PROPERTIES INC.
ATSG AIR TRANSPORT SERVICES GROUP INC.
APPS DIGITAL TURBINE
ANGO ANGIODYNAMICS INC.
AMPH AMPHASTAR PHARMACEUTICALS INC
AUP AURINIA PHARMACEUTICALS INC.
CRI CARTER'S INC.
LBRDA LIBERTY BROADBAND CORP. CLASS A
ASIX ADVANSIX INC.
CSCO CISCO SYSTEMS INC.
KREF KKR REAL ESTATE FINANCE TRUST
ROKU ROKU INC. CLASS A
PGC PEAPACK-GLADSTONE FINANCIAL CORP.
ZM ZOOM VIDEO COMMUNICATIONS INC. CLASS A
NVST ENVISTA HOLDINGS
MTCH MATCH GROUP INC.
GEVO GEVO
CGEM CULLINAN ONCOLOGY INC
OLPX OLAPLEX HLDGS INC
TSE TRINSEO PLC
EXFY EXPENSIFY INC
CCI CALAMOS GLB CNVRTBL & DYNMC INC COM
CSOAD COASTAL CONTACTS INC COM
- Research Team ACF
ACF Insight - Innovations in Oncology - the Future of Cancer Treatment...
Global oncology spending is projected to reach US$409bn by 2028E, up from US$223bn in 2023A at a 5yr CAGR of 11.5-14.5% from 2024-2028 (IQVIA, 2024). This growth is in part driven by US spending, which has increased to $99bn in 2023A up from $65bn in 2019A - the US makes up ~45% of global oncology spending.
Glycomimetics Inc: 1 director
A director at Glycomimetics Inc bought 305,000 shares at 0.258USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
- Research Team ACF
Regenerative Healthcare - Stem Cells & ALS Thematic 10062024
Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital. Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms. Within regenerative medicine we believe there ...
NOVN NOVARTIS AG
CG3 CELGENE CORPORATION
QURE UNIQURE NV
MRK MERCK & CO. INC.
JNJ JOHNSON & JOHNSON
GILD GILEAD SCIENCES INC.
CYTK CYTOKINETICS INCORPORATED
BMY BRISTOL-MYERS SQUIBB COMPANY
BIIB BIOGEN INC.
BCLI BRAINSTORM CELL THERAPEUTICS
SAN SANOFI
4523 EISAI CO. LTD.
IONS IONIS PHARMACEUTICALS INC.
WVE WAVE LIFE SCIENCES
PFE PFIZER INC.
ABBV ABBVIE INC.
AMRX AMNEAL PHARMACEUTICALS INC. CLASS A
TEVA TEVA PHARMACEUTICAL INDUSTRIES LIMITED
NOVO NOVO NORDISK A/S-B
Moody's says Gilead's acquisition of CymaBay will enhance liver produc...
Moody's Investors Service commented that Gilead Sciences, Inc.'s announcement that it would acquire publicly-traded CymaBay Therapeutics, Inc. for approximately $4.3 billion will enhance Gilead's expertise in liver disease and provides a solid growth opportunity, a credit positive. At the same time,...
Moody's announces completion of a periodic review of ratings of Gilead...
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Gilead Sciences, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 4 January 2024 in which Moody's reassessed the appropriateness of the rati...
Moody's announces completion of a periodic review of ratings of Gilead...
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Gilead Sciences, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 4 January 2024 in which Moody's reassessed the appropriateness of the rat...
- Dave Nicoski
- Ross LaDuke
ANTM ANTHEM INC.
TSN TYSON FOODS INC. CLASS A
RYAM RAYONIER ADVANCED MATERIALS INC
RY. ROYAL BANK OF CANADA
MRK MERCK & CO. INC.
LAZ LAZARD LTD CLASS A
KHC KRAFT HEINZ COMPANY
K KELLOGG COMPANY
GIS GENERAL MILLS INC.
GILD GILEAD SCIENCES INC.
FIBK FIRST INTERSTATE BANCSYSTEM INC. CLASS A
CVS CVS HEALTH CORPORATION
CPB CAMPBELL SOUP COMPANY
CNC CENTENE CORPORATION
CF CF INDUSTRIES HOLDINGS INC.
CAG CONAGRA BRANDS INC.
BGS B&G FOODS INC.
ARWR ARROWHEAD PHARMACEUTICALS INC.
ABUS ARBUTUS BIOPHARMA CORP.
VIRT VIRTU FINANCIAL INC. CLASS A
FDP FRESH DEL MONTE PRODUCE INC.
CENX CENTURY ALUMINUM COMPANY
KMI KINDER MORGAN INC CLASS P
KO COCA-COLA COMPANY
LMT LOCKHEED MARTIN CORPORATION
SJM J.M. SMUCKER COMPANY
ABBV ABBVIE INC.
MRNA MODERNA INC.
VTRS VIATRIS INC.
RLAY RELAY THERAPEUTICS
RNA AVIDITY BIOSCIENCES
DOLE DOLE PLC
- Dave Nicoski
- Ross LaDuke
WABC WESTAMERICA BANCORPORATION
RGR STURM RUGER & COMPANY INC.
PPC PILGRIM'S PRIDE CORPORATION
MCY MERCURY GENERAL CORPORATION
LDOS LEIDOS HOLDINGS INC.
IBCP INDEPENDENT BANK CORP. MICHIGAN
HMN HORACE MANN EDUCATORS CORPORATION
HII HUNTINGTON INGALLS INDUSTRIES INC.
GILD GILEAD SCIENCES INC.
EAT BRINKER INTERNATIONAL INC.
CUBI CUSTOMERS BANCORP INC.
CRK COMSTOCK RESOURCES INC.
CL COLGATE-PALMOLIVE COMPANY
BPMC BLUEPRINT MEDICINES CORP.
AR ANTERO RESOURCES CORPORATION
SAFT SAFETY INSURANCE GROUP INC.
AROW ARROW FINANCIAL CORP.
CHE CHEMED CORPORATION
NOC NORTHROP GRUMMAN CORPORATION
LMT LOCKHEED MARTIN CORPORATION
THG HANOVER INSURANCE GROUP INC.
WRB W. R. BERKLEY CORPORATION
ACNB ACNB CORP.
SRCE 1ST SOURCE CORP.
CSTR CAPSTAR FINANCIAL HOLDINGS
BL BEST LEASE
WRK WESTROCK COMPANY
NKE NIKE INC. CLASS B
ESSA ESSA BANCORP
CHMG CHEMUNG FINANCIAL CORP.
SRRK SCHOLAR ROCK HOLDING CORPORATION
ALXO ALX ONCOLOGY HOLDINGS
MODV MODIVCARE INC
VSCO VICTORIA'S SECRET & CO
CHK CHESAPEAKE ENERGY CORP
FRST PRIMIS FINANCIAL CORP
P RAILPOWER TECHNOLOGIES CORP.
MSBI HAMASHBIR 365 LTD
- Brian Moretta
- Mark Thomas
- Martin Hall
- Riccardo Bindi
Hardman & Co Monthly: April 2023
Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren...
INCY INCYTE CORP
IPN IPSEN SA
NOVN NOVARTIS AG
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
REGN REGENERON PHARMACEUTICALS INC.
LLY MERCK & CO. INC.
JNJ ELI LILLY AND COMPANY
J7Z JOHNSON & JOHNSON
HZNP JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
GILD HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
BMY GILEAD SCIENCES INC.
BIIB BRISTOL-MYERS SQUIBB COMPANY
FEV BIOGEN INC.
IBT FIDELITY EUROPEAN VALUES PLC
FCSS INTERNATIONAL BIOTECHNOLOGY TRUST PLC
FSV FIDELITY CHINA SPECIAL SITUATIONS PLC
FJV FIDELITY SPECIAL VALUES PLC
FAS FIDELITY JAPAN TRUST
AVO FIDELITY ASIAN VALUES PLC
CLIG ADVANCED ONCOTHERAPY
MRK CITY OF LONDON INVESTMENT GROUP
NOVO B MERCK KGAA
novob NOVO NORDISK A/S CLASS B
RECI NOVO NORDISK
SAN REAL ESTATE CREDIT INVESTMENTS
UCB SANOFI
HIK UCB S.A.
PIN HIKMA PHARMACEUTICALS PLC
PFIZER PANTHEON INTERNATIONAL
4506 PFIZER
4523 SUMITOMO DAINIPPON PHARMA CO. LTD.
4507 EISAI CO. LTD.
4568 SHIONOGI & CO. LTD.
VTAS DAIICHI SANKYO COMPANY LIMITED
STX VOLTA FINANCE (GBP)
4502 SHIELD THERAPEUTICS
HAT TAKEDA PHARMACEUTICAL CO. LTD.
OCI H&T GROUP
4578 OAKLEY CAPITAL INVESTMENTS
APAX OTSUKA HOLDINGS CO. LTD.
4503 APAX GLOBAL ALPHA
ICGT ASTELLAS PHARMA INC.
UTHR ICG ENTERPRISE TRUST
PFE UNITED THERAPEUTICS CORPORATION
AZN PFIZER INC.
GLAXO ASTRAZENECA PLC
ABBV GLAXOSMITHKLINE PHARMACEUTICALS
VRX CN ASTELLAS PHARMA INC
MRNA ABBVIE INC.
TXG BAUSCH HEALTH COMPANIES INC.
NOVO MODERNA INC.
VTRS 10X GENOMICS INC CLASS A
4568.T NOVO NORDISK A/S-B
ME VIATRIS INC.
OCL DAIICHI SANKYO COMPANY
LUND A LIMITED
23ANDME HLDG CO
OAKLEY CAPITAL
H. LUNDBECK A/S
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.